論文

査読有り
2019年2月15日

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.

Internal medicine (Tokyo, Japan)
  • Masaki Mitobe
  • Keisuke Kawamoto
  • Takaharu Suzuki
  • Maiko Kiryu
  • Suguru Tamura
  • Ayako Nanba
  • Tatsuya Suwabe
  • Tomoyuki Tanaka
  • Kyoko Fuse
  • Yasuhiko Shibasaki
  • Masayoshi Masuko
  • Hiroaki Miyoshi
  • Koichi Ohshima
  • Hirohito Sone
  • Jun Takizawa
  • 全て表示

58
4
開始ページ
575
終了ページ
580
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2169/internalmedicine.1686-18

A 61-year-old woman exhibited right inguinal lymphadenopathy and right lower limb edema approximately 1 month prior to hospitalization. She was diagnosed with high grade B-cell lymphoma, and a lymph node biopsy and fluorescence in situ hybridization indicated MYC, BCL2, and BCL6 rearrangements (triple-hit lymphoma). She had progressive disease that was CD20-negative after two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high-dose cytarabine (R-CODOX-M/IVAC) therapy. Subsequent etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (EPOCH) therapy was not effective. However, after two cycles of gemcitabine, dexamethasone, and cisplatin (GDP) therapy, she achieved a complete response and was able to undergo autologous peripheral blood stem cell transplantation. GDP therapy may be effective as salvage therapy for chemotherapy-resistant triple-hit lymphoma.

リンク情報
DOI
https://doi.org/10.2169/internalmedicine.1686-18
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30210134
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421138
ID情報
  • DOI : 10.2169/internalmedicine.1686-18
  • ISSN : 0918-2918
  • PubMed ID : 30210134
  • PubMed Central 記事ID : PMC6421138

エクスポート
BibTeX RIS